Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267.
   PubMed Web of Science ®Google Scholar
• Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(9):e600. doi:10.1038/bcj.2017.83.
   PubMed Web of Science ®Google Scholar
• Chretien ML, Corre J, Lauwers-Cances V, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126(25):2713–2719. doi:10.1182/blood-2015-06-650242.
   PubMed Web of Science ®Google Scholar
• Fu Q, Xie S, Chen J, Huang H. Modified culture system and combination of FICTION could increase the detection rate of abnormalities in multiple myeloma. Ann Clin Lab Sci. 2021;51:61–72.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101(11):2667–2674. doi:10.1002/cncr.20652.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. doi:10.4065/78.1.21.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477. doi:10.1136/bmj.477.
   PubMed Web of Science ®Google Scholar
• Bird S, Cairns D, Menzies T, et al. Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma XI trial. Clin Lymphoma Myeloma Leuk. Oct 2021;21(10):667–675. doi:10.1016/j.clml.2021.04.013.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962. doi:10.1182/blood-2016-01-631200.
   PubMed Web of Science ®Google Scholar
• Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95(6):1925–1930. doi:10.1182/blood.V95.6.1925.
   PubMed Web of Science ®Google Scholar
• Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100–2105. doi:10.1182/blood-2011-11-390658.
   PubMed Web of Science ®Google Scholar
• Mellors PW, Binder M, Ketterling R, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020;4(10):2236–2244. doi:10.1182/bloodadvances.2019001275.
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions. Ophthalmology. 2004;111(5):997–1008. doi:10.1016/j.ophtha.2003.01.002.
   PubMed Web of Science ®Google Scholar
• Thuro BA, Sagiv O, Shinder R, et al. Clinical presentation and Anatomical Location of Orbital Plasmacytomas. Ophthalmic Plast Reconstr Surg. 2018;34(3):258–261. doi:10.1097/IOP.0000000000000939.
   PubMed Web of Science ®Google Scholar
• Zloto O, Vahdani K, Stack R, Verity DH, Rose GE. Periocular presentation of Solitary Plasmacytomas and Multiple Myeloma. Ophthalmic Plast Reconstr Surg. 2022;38(2):180–184. doi:10.1097/IOP.0000000000002023.
   PubMed Web of Science ®Google Scholar
• Kumar L, Gogi R, Patel AK, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant. 2017;52(10):1473–1475. doi:10.1038/bmt.2017.165.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–858. doi:10.1111/bjh.13383.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–284. doi:10.1111/j.1365-2141.2004.05199.x.
   PubMed Web of Science ®Google Scholar
• Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161(1):87–94. doi:10.1111/bjh.12223.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema D-J, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–897. doi:10.3324/haematol.2017.178434.
   PubMed Web of Science ®Google Scholar
• Brink M, Groen K, Sonneveld P, et al. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer J. 2021;11(11):178. doi:10.1038/s41408-021-00571-8.
   PubMed Web of Science ®Google Scholar
• Chretien ML, Hebraud B, Cances-Lauwers V, et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica. 2014;99(7):1236–1238. doi:10.3324/haematol.2013.098608.
   PubMed Web of Science ®Google Scholar